首页> 外文OA文献 >C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations
【2h】

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations

机译:C /EBPα调控的microRNA-34a在粒细胞生成过程中靶向E2F3,并在具有CEBPA突变的AML中被下调

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The transcription factor, CCAAT enhancer binding protein alpha (C/EBPα), is crucial for granulopoiesis and is deregulated by various mechanisms in acute myeloid leukemia (AML). Mutations in the CEBPA gene are reported in 10% of human patients with AML. Even though the C/EBPα mutants are known to display distinct biologic function during leukemogenesis, the molecular basis for this subtype of AML remains elusive. We have recently showed the significance of deregulation of C/EBPα-regulated microRNA (miR) in AML. In this study, we report that miR-34a is a novel target of C/EBPα in granulopoiesis. During granulopoiesis, miR-34a targets E2F3 and blocks myeloid cell proliferation. Analysis of AML samples with CEBPA mutations revealed a lower expression of miR-34a and elevated levels of E2F3 as well as E2F1, a transcriptional target of E2F3. Manipulation of miR-34a reprograms granulocytic differentiation of AML blast cells with CEBPA mutations. These results define miR-34a as a novel therapeutic target in AML with CEBPA mutations.
机译:转录因子CCAAT增强子结合蛋白α(C /EBPα)对于粒细胞生成至关重要,在急性髓细胞性白血病(AML)中受多种机制抑制。据报道,在患有AML的人类患者中,有10%的人患有CEBPA基因突变。即使已知C /EBPα突变体在白血病发生过程中表现出独特的生物学功能,但这种AML亚型的分子基础仍然难以捉摸。我们最近显示了在AML中放松C /EBPα调控的microRNA(miR)的重要性。在这项研究中,我们报道了miR-34a是粒细胞生成中C /EBPα的新靶标。在粒细胞生成过程中,miR-34a靶向E2F3,并阻止髓样细胞增殖。对具有CEBPA突变的AML样品的分析显示,miR-34a的表达水平较低,E2F3以及E2F1(E2F3的转录靶标)的水平升高。对miR-34a的操作会重新编程具有CEBPA突变的AML原始细胞的粒细胞分化。这些结果将miR-34a定义为具有CEBPA突变的AML中的新型治疗靶标。

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号